applera corporation norwalk connecticut fortune list one largest international biotechnology companies based united states successor company life sciences division perkinelmer corporation applera publicly traded instead consisted two major groups publicly traded tracking stocks proteomics industrial sector two groups sp listed applera corpapplied biosystems group foster city california applera corpcelera genomics group rockville maryland company spun celera genomics group changed name applera applied biosystems former perkinelmer applera history dating back precisely history dates perkinelmer effectively split half sold traditional half business egg inc part deal also sold perkinelmer name properly associated traditional line products egg became new perkinelmer point remaining connecticut life sciences company issued two tracking stocks also changed name pe corporation applied biosystems group earlier already renamed pe biosystems retained name first incarnation tracking stock applied biosystems name restored group new stock ticker symbol abi pe corporation became applera combination two components names applera corporation directors oversaw parent corporation along operations tracking stock groups consequently responsibility fairly balancing interests groups investors original perkinelmer successor pe corporation applera corporation headquartered norwalk connecticut company address danbury early perkinelmer maker diverse electronic instruments analytical optical established strong ties groups closely involved business decoding human genome late perkinelmers life sciences division become centrally involved highly publicized intense competition public consortium also working massive task consequently perkinelmers people companies became among famous players decade biotechnology segment technology bubble process perkinelmer divided transformed applera company entirely focused life sciencescitation needed beginning us government approved financing support human genome project hgp james watson founded public consortium forecast project could completed years starting date cost hgp public consortium eight university centers funded us department energy national institutes health wellcome trust london governmentbacked project targeted completion human dna mapping year perkinelmer acquired key equipment maker applied biosystems inc stocks symbol abio ceased trading nasdaq exchange became division perkinelmer michael w hunkapiller phd applied biosystems chairman president ceo since became senior vice president perkinelmer president applied pe biosystems perkinelmer reported net revenues billion life sciences accounted business company employees new competitive genomics industry formed development new pharmaceuticals based work human genome project applied biosystems division made thermal cyclers automated sequencers new genomics perkinelmer sold thermal cycler meet human genome project goals perkinelmer developed mapping kits markers every million bases along chromosome also year dna fingerprinting using polymerase chain reaction pcr became accepted court reliable forensic evidence perkinelmer become worlds leading manufacturer instruments reagents pcr marketed pcr reagents kits alliance hoffmanla roche perkinelmer acquired tropix inc chemiluminescence company life sciences also tony l white baxter international inc became president chief executive officer perkinelmer reorganized two separate operating divisions analytical instruments pe applied biosystems pe applied biosystems division accounted half perkinelmers total revenue net revenues perkinelmer revenues reached almost billion pe applied biosystems million acquisitions included genscope inc linkage genetics inc combined zoogen form pe aggen focused genetic analysis services plant animal breeding partnerships begun hyseq inc new dna chip technology also tecan us inc combinatorial chemistry automation systems also molecular informatics inc genetic data management analysis automated perkinelmer acquired perseptive biosystems formerly nasdaq pbio leader bioinstrumentation field made biomolecule purification systems protein noubar afeyan phd founder chairman ceo perseptive acquisition became senior vice president chief business officer perkinelmer earlier founded cobuilt several successful life science technology startup companies earning phd biochemical engineering massachusetts institute technology perkinelmer formed pe biosystems division consolidating applied biosystems perseptive biosystems tropix pe informatics informatics formed perkinelmer combination two acquisitions molecular informatics nelson analytical systems existing units perkinelmer presence world wide web planning next new generation machines pe biosystems president michael w hunkapiller calculated would possible private industry decode human genome academic consortium could complete company would decode billion chemical letters human dna cost million consortium projected cost however would mean starting scratch eight years already consortiums bold prediction given consortium target date set watson back forward year seven years away consortium already half way completion target date thencitation needed also meant hunkapillers idea would require competing customers applied biosystems sold sequencing machines chemical reagents however calculated would also mean doubling market hunkapiller brought j craig venter direct project tony l white president perkinelmer corporation backed hunkapiller venture perkinelmers interest driven largely monopoly equipment applied biosystems market automated dna sequencing machines venter boldly declared media would complete genome decoding bold pronouncement prompted academic consortium accelerate deadline couple years may companys newly formed unit accomplish task celera genomics group rockville maryland created become definitive source genomic related medical information goal sequencing human genome year celera became primary commercial competitor governmentfunded effort human genome project venter became president chief scientific officer time venter operated independent lab institute genomic research tigr developed random shotgun approach dna decoding making prolific genome lab year end pe biosystems groups sales reached million chief new genomics instrument abi prism dna analyzer developed conjunction hitachi new machine electrophoresisbased genetic analysis system cost major leap beyond predecessor fully automated allowing genetic decoding run around clock little according venter machine revolutionary could decode single day amount genetic material dna labs could produce partnership sold hundreds analyzers celera also others public consortium also bought one applied biosytems sequencers plans buy machine proved fast late march consortium announced revised timeline would release spring first draft sequence human march perkinelmer corporation new york corporation filed sec form enter reincorporation merger subsidiary pe corporation delaware shareholders new york corporation stock nysepkn would receive shares two new stocks april shareholders perkinelmer corporation approved reorganization perkinelmer pureplay life science resulting name change pe corporation delisting pkn stock share perkinelmer new york pkn exchanged one share share respectively two new common share tracking stocks two component life sciences groups pe biosystems group nysepeb celera genomics group pkn april two replacement tracking stocks new pe corporation issued pacific stock exchange began trading pe corporation options two new stocks michael w hunkapiller remained senior vice president pe corporation president pe afeyan initiated oversaw creation tracking stock celera genomics later afeyan left cofound flagship ventures earlystage entrepreneurial venture capital j craig venter remained senior vice president pe corporation also president celera genomics group tony l white remained pe corporations chairman president chief executive officers remained pe corporation included william b sawch senior vice president general counsel may reorganization made effective perkinelmer corporation merged temporarily created subsidiary pe corporation new delaware corporation recapitalization company resulted issuance two new classes common stock called pe corporationpe biosystems group common stock pe corporationcelera genomics group common date trading began new stocks new york stock exchange great may part recapitalization reorganization company completed sale traditional business unit analytical instruments division egg inc along perkinelmer name egg based wellesley massachusetts made products diverse industries including automotive medical aerospace photography july new analytical instruments maker perkinelmer cut jobs cost reduction june board pe corporation announced twoforone split pe biosystems group common year end major divestment year former analytical instruments division new pe corporation assets totalled billion split two life sciences pe biosystems group employees net revenues june genomics segment technology bubble peaking celera genomics cra pe biosystems peb among five genetics pioneers leading time along incyte genomics nasdaq incy human genome sciences nasdaq hgsi millennium pharmaceuticals nasdaq mlnm five stocks exceeded price share market ultimately crashing back november pe corporation filed sec form report announcement change name applera corporation time pe biosystems group changed name applied biosystems group changed ticker symbol peb abi name changes became effective november also date parent corporation web site address changed combined applera employees peapplied biosystems groups net revenues rose almost billion celera year made milestone headlines announced completed sequencing first assembly two largest genomes history fruit fly applied biosystems division applera reached revenues billion developed new workstation instrument specifically new field proteomics become celeras new core business focus shifted away gene discovery instrument analyzed protein samples per january j craig venter pushed celera decided group would make pharmaceuticals instead venter lacked experience pharmaceutical april celera genomics group announced decision abandon core business since inception shift role marketing data genetic database sister company applied biosystems group celera would instead develop pharmaceutical drugs applera ceo tony l white noted earlier database business would distract pharmaceutical applied biosystems better fit database applied already huge sales force place marketing instruments plans expand sales database electronic commerce database celera discovery system would remain celera shareholder approval complications celera would retain responsibility maintenance support existing customers would receive royalties applied biosystems database revenues expected reach million june fiscal year end would first profitable year always faced problem public competitor consortium project provides free data applied biosystems group posted revenues billion longterm applied biosystems president mike hunkapiller retired cathy burzik joined group replaced president applied biosystems httpsenwikipediaorgwikiapplera